Category REGENERATIVE MEDICINE

Researchers of UEF unraveled new mechanisms behind articular cartilage healing after injury

Understanding how the knee joint environment affects cartilage cells is crucial for joint health. Knowledge of cell-driven cartilage degeneration mechanisms can support the development of effective pharmaceutical interventions for osteoarthritis. The burden of musculoskeletal diseases, such as osteoarthritis, is increasingly affecting patients’ quality of life and bringing enormous costs to health care. In efforts to

Read More


The Texas Heart Institute Delivers a New First in Heart Failure Treatment Using Cell Therapy

New Cell Therapy Offers Potential Treatment Option for Patients With Chronic Heart Failure Physician-scientists at The Texas Heart Institute announced today the results of the largest cell therapy trial to date in patients with chronic heart failure due to low ejection fraction. The therapy benefited patients by improving the heart’s pumping ability, as measured by

Read More


Duke-NUS and NHCS scientists first in the world to regenerate diseased kidney

Blocking an immune-regulating protein reverses the damage caused by acute and chronic kidney disease, a preclinical study suggests. Led by scientists at Duke-NUS Medical School and the National Heart Centre Singapore, researchers in Singapore and Germany have found that renal tubular cells, which line the tiny tubes inside kidneys, release a scar-regulating protein called interleukin-11

Read More


T lymphocytes engineering: advances in treatment of cancer, autoimmune diseases, scarring and beyond

In recent months there have been some major jumps—unprecedented success stories—that indicate our ability to engineer T cells may well have a substantial impact for multiple medical conditions that have not been responsive to conventional therapies or for which there is no available treatment. This can be regarded as the quintessential individualized medicine intervention—specifically modifying

Read More


Results on 5 gene therapy trials expected in the first 2023 semester

Can gene therapy trials for vision loss, hemophilia, and melanoma break through in 2023? fter another turbulent year in gene therapy development, all eyes are on five major trial readouts set for H1 2023. The clinical studies target rare blood disorders, inherited retinal diseases, and metastatic melanoma—each of which poses distinct trial design challenges. First, two small

Read More


Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial with a 99% response rate

An innovative immunotherapy combination has shown a stunning 99% response rate in children with relapsed leukemia. The phase 2 trial, run jointly between researchers at St. Jude Children’s Research Hospital in Memphis and Shanghai Children’s Hospital in China tested the therapy in 225 children who had relapsed after conventional treatment. The work published in the Journal

Read More


Two synthetic biology experiments offer hope for future cancer treatments with CAR-T cells

New immunotherapies can allow healing cells to be activated or deactivated according to the stage of the disease, while more accurately targeting tumors While CAR T therapy represents one of the most impressive innovations in cancer care, the treatment can cause autoimmune-like side effects. Many have contended with the dilemma of maximizing the therapy’s benefits

Read More


Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate

 Pfizer announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult males with moderately severe to severe hemophilia B. The BENEGENE-2 study met its primary endpoint of non-inferiority and superiority in the annualized bleeding rate (ABR) of total bleeds post-fidanacogene elaparvovec infusion

Read More